Clinical experiences with systemically administered siRNA-based therapeutics in cancer

Physical Chemistry of Nanomedicine: Understanding the Complex Behaviors of Nanoparticles in Vivo

(2015) Lucas A. Lane et al.   Annual Review of Physical Chemistry

Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model

(2015) Gregory R. Robbins et al.   Nanomedicine-Nanotechnology Biology and Medicine

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

(2015) R. Dienstmann et al.   Cancer Discovery

Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency

(2014) Edward A. Sykes et al.   ACS Nano

Beyond BRAF: where next for melanoma therapy?

(2014) I V Fedorenko et al.   BRITISH JOURNAL OF CANCER

Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis

(2014) Sonia A. Melo et al.   CANCER CELL

First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors

(2014) Beate Schultheis et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates

(2014) Stephanie E. Barrett et al.   JOURNAL OF CONTROLLED RELEASE

Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

(2014) Jayaprakash K. Nair et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer

(2014) C. L. Daige et al.   MOLECULAR CANCER THERAPEUTICS

MicroRNA silencing for cancer therapy targeted to the tumour microenvironment

(2014) Christopher J. Cheng et al.   NATURE

Time to deliver

(2014)   NATURE BIOTECHNOLOGY

Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates

(2014) Trinna L. Cuellar et al.   NUCLEIC ACIDS RESEARCH

Long-Distance Communication between Laryngeal Carcinoma Cells

(2014) Ieva Antanavičiūtė et al.   PLoS One

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

(2014) J. E. Zuckerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Investigating the optimal size of anticancer nanomedicine

(2014) L. Tang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of RNA structure at 5′ untranslated region in microRNA-mediated gene regulation

(2014) Wanjun Gu et al.   RNA

The new frontier of genome engineering with CRISPR-Cas9

(2014) J. A. Doudna et al.   SCIENCE

RNAi Therapies: Drugging the Undruggable

(2014) S. Y. Wu et al.   Science Translational Medicine

Antisense therapeutics in oncology: current status

(2014) Ammad Ahmad Farooqi et al.   OncoTargets and Therapy

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

(2014) Kathryn A. Whitehead et al.   Nature Communications

Development of siRNA Payloads to Target KRAS-Mutant Cancer

(2014) T. L. Yuan et al.   Cancer Discovery

Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology

(2013) Nicolas Bertrand et al.   ADVANCED DRUG DELIVERY REVIEWS

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

(2013) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

(2013) U. Prabhakar et al.   CANCER RESEARCH

Vesicle Trafficking and RNA Transfer Add Complexity and Connectivity to Cell-Cell Communication

(2013) C. T. Roberts et al.   CANCER RESEARCH

Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology

(2013) Lígia Catarina Gomes-da-Silva et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Intercellular Communication by Exosome-Derived microRNAs in Cancer

(2013) Bethany Hannafon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

(2013) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

(2013) Kevin Fitzgerald et al.   LANCET

Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

(2013) Neil Senzer et al.   MOLECULAR THERAPY

Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

(2013) Martin A Maier et al.   MOLECULAR THERAPY

Heterogeneity in nanoparticles influences biodistribution and targeting

(2013) Isaac M Adjei et al.   Nanomedicine

Delivery materials for siRNA therapeutics

(2013) Rosemary Kanasty et al.   NATURE MATERIALS

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

(2013) Teresa Coelho et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Significance of Deregulated Dicer Expression in Breast Cancer

(2013) Emer Caffrey et al.   PLoS One

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

(2013) S. Eliasof et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CRISPR Craze

(2013) E. Pennisi   SCIENCE

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

(2013) Josep Tabernero et al.   Cancer Discovery

Toxicity profiling of several common RNAi-based nanomedicines: a comparative study

(2013) Dalit Landesman-Milo et al.   Drug Delivery and Translational Research

Safety profile of RNAi nanomedicines

(2012) Scott A. Barros et al.   ADVANCED DRUG DELIVERY REVIEWS

Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models

(2012) Atsushi Suetsugu et al.   ADVANCED DRUG DELIVERY REVIEWS

Cancer nanomedicines: So many papers and so few drugs!

(2012) Vincent J. Venditto et al.   ADVANCED DRUG DELIVERY REVIEWS

In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier

(2012) Broes Naeye et al.   BIOMATERIALS

RNA-Based Therapeutics: Current Progress and Future Prospects

(2012) John C. Burnett et al.   CHEMISTRY & BIOLOGY

Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research

(2012) Susana Patricia Egusquiaguirre et al.   Clinical & Translational Oncology

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

(2012) Gina Song et al.   JOURNAL OF LIPOSOME RESEARCH

Nanoparticle Hydrophobicity Dictates Immune Response

(2012) Daniel F. Moyano et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Assessing the Heterogeneity Level in Lipid Nanoparticles for siRNA Delivery: Size-Based Separation, Compositional Heterogeneity, and Impact on Bioperformance

(2012) Jingtao Zhang et al.   MOLECULAR PHARMACEUTICS

Fighting cancer with nanoparticle medicines―The nanoscale matters

(2012) Mark E. Davis   MRS BULLETIN

Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane

(2012) J. E. Zuckerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities

(2012) Z. Cheng et al.   SCIENCE

Therapeutic Oligonucleotides: The Road Not Taken

(2011) C. A. Stein et al.   CLINICAL CANCER RESEARCH

Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery

(2011) L Li et al.   GENE THERAPY

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors

(2011) Dirk Strumberg et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Atelocollagen-mediated Systemic Delivery Prevents Immunostimulatory Adverse Effects of siRNA in Mammals

(2011) Shinichiro Inaba et al.   MOLECULAR THERAPY

Progress Toward In Vivo Use of siRNAs-II

(2011) Garrett R Rettig et al.   MOLECULAR THERAPY

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

(2011) H. Cabral et al.   Nature Nanotechnology

The Dicey Role of Dicer: Implications for RNAi Therapy

(2010) William M. Merritt et al.   CANCER RESEARCH

Potential clinical applications of siRNA technique: benefits and limitations

(2010) Shao-Hua Chen et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide

(2010) Jonathan E. Zuckerman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

(2010) Mark E. Davis et al.   NATURE

Strategies in the design of nanoparticles for therapeutic applications

(2010) Robby A. Petros et al.   NATURE REVIEWS DRUG DISCOVERY

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

(2009) Adam D. Judge et al.   JOURNAL OF CLINICAL INVESTIGATION

siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury

(2009) B. A. Molitoris et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic

(2009) Mark E. Davis   MOLECULAR PHARMACEUTICS

Knocking down barriers: advances in siRNA delivery

(2009) Kathryn A. Whitehead et al.   NATURE REVIEWS DRUG DISCOVERY

Challenges and Opportunities for Local and Systemic Delivery of siRNA and Antisense Oligonucleotides

(2008) L Sepp-Lorenzino et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Nanoparticle therapeutics: an emerging treatment modality for cancer

(2008) Mark E. Davis et al.   NATURE REVIEWS DRUG DISCOVERY

Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer

(2008) William M. Merritt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemical Modification of siRNAs for In Vivo Use

(2008) Mark A. Behlke   OLIGONUCLEOTIDES

Stability Study of Unmodified siRNA and Relevance to Clinical Use

(2008) Robyn P. Hickerson et al.   OLIGONUCLEOTIDES

Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles

(2007) Derek W. Bartlett et al.   BIOTECHNOLOGY AND BIOENGINEERING